

Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes

Jennifer L. Fisher¹, Amanda D. Clark¹, Emma F. Jones¹, and Brittany N. Lasseigne^{1*}.

1. Department of Cell, Developmental and Integrative Biology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA

* Corresponding Author: bnp0001@uab.edu

Summary

Within the scientific literature, it has been identified that women are almost twice as likely to experience undesired drug side effects compared to men. Men are more likely to experience severe drug side effects that result in hospitalization or death. To better understand potential genomic causes of these sex-dependent drug responses, we investigated drug side effects that are more likely to be reported by either males or females, known as sex-biased adverse events (SBAEs). In this study, we identified 32 drug metabolism enzymes and 84 drug targets enriched across the known drug metabolism enzymes and targets of the 416 drugs we found associated with SBAEs. Several known drug metabolism enzymes and drug targets of SBAE-associated drugs have sex differences in gene expression or gene-regulatory networks representing the relationships between genes and the transcription factors predicted to regulate their expression. Overall, we found an association between sex differences in gene expression and predicted gene-regulatory relationships of drug metabolism enzymes and drug targets associated with SBAEs. Additionally, our findings are a resource of sex-biased drug-adverse event pairs and gene expression profiles for the scientific community.

Abstract

Background:

Previous pharmacovigilance studies and a retroactive review of cancer clinical trial studies identified that women were more likely to experience drug adverse events (i.e., any unintended effects of medication), and men were more likely to experience adverse events that resulted in hospitalization or death. These sex-biased adverse events (SBAEs) are due to many factors not entirely understood, including differences in body mass, hormones, pharmacokinetics, and liver drug metabolism enzymes and transporters.

Methods:

We first identified drugs associated with SBAEs from the FDA Adverse Event Reporting System (FAERS) database. Next, we evaluated sex-specific gene expression of the known drug targets and metabolism enzymes for those SBAE-associated drugs. We also constructed sex-specific tissue gene-regulatory networks to determine if these known drug targets and metabolism enzymes from the SBAE-associated drugs had sex-specific gene-regulatory network properties and predicted regulatory relationships.

Results:

We identified liver-specific gene-regulatory differences for drug metabolism genes between males and females, which could explain observed sex differences in pharmacokinetics and pharmacodynamics. In addition, we found that ~85% of SBAE-associated drug targets had sex-biased gene expression or were core genes of sex- and tissue-specific network communities, significantly higher than randomly selected drug targets. Additionally, the number of SBAE-associated drug targets that were core genes of sex- and tissue-specific network communities were significantly higher than randomly selected drug targets. Lastly, we

provide the sex-biased drug-adverse event pairs, drug targets, and drug metabolism enzymes as a resource for the research community.

Conclusions:

Overall, we provide evidence that many SBAEs are associated with drug targets and drug metabolism genes that are differentially expressed and regulated between males and females. These SBAE-associated drug metabolism enzymes and drug targets may be useful for future studies seeking to explain or predict SBAEs.

Highlights

- Sex-biased adverse events have been identified in previous pharmacovigilance studies.
- We found that 416 drugs associated with sex-biased adverse events were enriched for 32 known drug metabolism enzymes and 84 drug targets.
- Drug metabolism enzyme genes of known SBAE-associated drugs have sex differences in predicted liver gene-regulatory network neighborhoods (i.e., immediate node neighbors) and individual transcription factor and gene relationships.
- SBAE-associated drug targets are more likely to have sex-biased gene expression and be core genes of sex-specific network communities than other drug targets.
- Drugs with these SBAE-associated drug metabolism enzymes and drug targets should be investigated further to determine causal relationships.

Background

In the U.S., adverse events (defined by the U.S. Food and Drug Administration [FDA] as any undesirable experience associated with using a medical product) resulted in an annually estimated 1.3 billion emergency room visits and an approximate 3.5 billion dollar economic impact [1–3]. Adverse events that are more likely to occur in one sex are called sex-biased adverse events (SBAEs) [4]. In 2001, the FDA removed ten drugs from the market; eight had female-biased adverse events [5]. Since then, several studies have found that women are twice as likely to experience an adverse event than men, based on adverse event case reports from the FDA Adverse Event Reporting System (FAERS) and World Health Organization (WHO) VigiBase database [6–10]. A retroactive review of cancer clinical trial studies found that women were more likely to experience adverse events from chemotherapy and immunotherapies [9]. On the other hand, a VigiBase study found that men were more likely to experience adverse events that resulted in hospitalization or death [7]. Furthermore, the gender gap between men and women in the number of female-biased SBAEs increased during the coronavirus disease 2019 (COVID-19) pandemic [8].

While there are multiple sources of evidence for SBAEs, the biological differences that might result in SBAEs are still being investigated. Proposed causes of SBAEs include, but are not limited to, sex differences in body mass, hormones, pharmacokinetics, and liver drug metabolism enzymes and transporters [4]. One early hypothesis was that body mass differences between males and females resulted in SBAEs. While body mass differences are a known factor for drug response outcomes, many SBAEs are not explained by body mass differences [11,12]. Sex hormone differences have also been hypothesized to cause SBAEs and found to compete for drug transporters, compete with and inhibit enzymes, alter transcription, and interact with receptors on target cells [13]. Another previously investigated drug response factor is pharmacodynamics and pharmacokinetics [11]. Multiple studies have found sex differences in several pharmacokinetic metrics, such as the area under the curve of the plasma concentration of a drug versus time after dose or peak/maximum concentration [11]. Other studies have shown that many drug metabolism enzymes have differential gene expression and protein activity in male and female liver tissue [14–16]. Additionally, Oliva, et al. showed that in the Genotype-Tissue Expression (GTEx) project (n = 16,245 RNA-sequencing samples across 44 human tissues), 37% of genes had sex-biased tissue-specific expression and that these genes were enriched in drug metabolism gene sets (i.e., Gene Ontology [GO] and Kyoto Encyclopedia of Genes and Genomes [KEGG])

terms: “Xenobiotic Metabolism, Mitochondrial Genes and Fatty Acid Oxidation,” “ Cellular Response to Hormones and Drugs,” “Drug Interaction and Response,” and “Drug Interaction”) [17].

Other studies have shown that regulatory relationships between transcription factors and genes differ between males and females in a tissue-specific manner [18,19]. For example, a previous study in colon cancer patients applied gene-regulatory network construction to colon cancer gene expression profiles from The Cancer Genome Atlas (TCGA) project and found that drug metabolism genes were more targeted in the female network than the male network in tumor tissue [20]. Sex-specific gene-regulatory networks of breast tissue have also shown sex differences in network communities (i.e., groups of transcription factors and genes that are more interconnected than other genes in the network) involved in different pathways, such as developmental and signaling pathways [18]. These sex differences in gene-regulatory networks across tissues could be potential factors in SBAEs.

We hypothesized that drug metabolism enzymes and drug targets of drugs associated with SBAEs had sex-biased gene-regulatory network properties compared to other genes and drug targets (**Figure 1**). First, we identified 416 drugs associated with SBAEs (i.e., SBAE-associated drugs) from cases reported in the FAERS database. We found that 32 drug metabolism enzymes and 84 drug targets were more likely to be targets of these SBAE-associated drugs than non-SBAE-associated drugs. KEGG-annotated drug metabolism genes also had sex differences in their liver gene-regulatory network neighborhoods and individual transcription factor gene relationships. For the 84 SBAE-associated drug targets, we found that their gene expression was more likely to be sex-biased and for those genes to be core genes (i.e., essential genes for gene-regulatory network community identification). These results support our hypothesis that the known drug metabolism enzymes and drug targets of drugs associated with SBAE have sex differences in gene expression and gene-regulatory networks.




Figure 1: Graphical abstract of the study.

Methods:

Scripts, dockers, and conda environment:

The scripts for this project are available on Zenodo at <https://zenodo.org/record/7938613#.ZGKFpdbMlaQ>. In addition to the scripts there, the Docker images used for this analysis are publicly available on Docker Hub (jenfisher7/rstudio_sex_bias_drugs) and Zenodo (<https://zenodo.org/record/7941598#.ZGOW5tbMKJE>) (R version 4.2.2). For Fisher's exact test calculations, we used a conda environment on the University of Alabama's high-performance system, Cheaha, in an array format (SR_TAU_CELL_environment.yml) (R version 4.0.5).

Comprehensive computer environment and package version information is included in **Supplemental File 1**.

Data download and exploration:

Medical Dictionary for Regulatory Activities (MedDRA):

We downloaded the MedDRA database in July 2022 (Version 25.0). This database contains a 5-level hierarchy of medical terminology from lowest-level terms (e.g., "abnormal EEG") to preferred terms (e.g., "electroencephalogram abnormal"), and finally to their highest-level terms, the system organ class terms (e.g., "investigations"). FAERS case reports contain MedDRA lower-level and preferred terms to annotate adverse events. We mapped all the lower-level terms to the system organ class terms to investigate groups of preferred terms and system organ class terms in the context of SBAEs.

The MedDRA database is a subscription database. We provide the workflow we used to format the downloaded database to the mappings used for the rest of this study in the provided scripts above.

FAERS:

We downloaded curated FDA Adverse Event Reporting System (FAERS) data from the Zhang et al. study [8]. The FAERS database contains case reports of reported adverse events. We filtered the curated cases by country (i.e., "US"), qualification of the reporting party (i.e., "1" = physician, "2" = pharmacist, "3" = other health professionals), and cases that contained information for both sex (i.e., "gender") and drugs. We also converted any lower-level MedDRA adverse event terms to their preferred terms via the MedDRA mappings described above. We only retained the newest case report for the three duplicated cases we identified.

GTEX:

We downloaded preprocessed RNA-Seq count tables and metadata for the GTEx project with the Recount3 R package (version 1.8.0; accessed March 2022). We removed the sample GTEX-11 ILO, identified in previous literature as an individual who completed a gender-affirming surgery [21]. We also filtered samples to only those sequenced with the TRUSeq.v1 chemistry. We removed the following tissues due to being a sex-specific tissue or there being less than five samples in one sex: cervix-ectocervix, cervix-endocervix, fallopian tube, kidney-medulla, ovary, uterus, vagina, prostate, and testis. We also removed samples with a RIN score less than or equal to five. We recorded the final number of samples by sex for each tissue in **Supplemental File 2**.

In addition, we used the base R `prcomp` function to perform a principal component analysis (PCA) of the GTEx liver tissue samples to determine potentially confounding variables (i.e., age, RIN score, and ischemic time) that may affect gene expression and downstream results. We transformed the gene counts via DESeq2 (version 1.38.2) variance stabilizing transformation (`vst`). Then, we visually inspected PCA one through five for clustering of samples based on age, RIN score, and ischemic time. We found samples clustered by ischemic time and RIN score with PC 1 (19.09% of variance explained) and PC 2 (8.916% of variance explained). These had a negative Spearman correlation with one another ($\rho = -0.5652864$).

The methodology used to construct gene-regulatory networks, Passing Attributes between Networks for Data Assimilation (PANDA), required gene expression profiles. Before normalizing the GTEx data above, we filtered out genes with less than one count per million across all samples. We normalized the gene expression counts with a quantile shrinkage normalization via the R package YARN `qsmooth` function (version 1.24.0) [21] to remove variation due to technical variables in an unsupervised manner but with the "group" parameter to normalize the filtered counts data in a sex-aware manner to maintain the biological signal related to sample sex [21].

Protein-protein interaction and transcription factor motif information for gene-regulatory networks:

The gene-regulatory network analysis required protein-protein interaction, transcription motif information, and RNA-Seq profiles. We downloaded the human protein-protein interaction network from the STRING database (accessed date: Jan. 2023; version 11.5). We adjusted this network of known and predicted

protein-protein interactions, including direct and indirect associations, for downstream gene-regulatory network construction by transforming edge weights to be between zero and one and focusing on highly confident interactions. To achieve this data transformation, we divided the raw interaction scores by 1000 and filtered for interactions greater than 0.7. We converted protein Ensembl IDs to HGNC gene symbols with the protein metadata in STRING. Additionally, we downloaded preprocessed transcription factor motif mapping (accessed date: Jan. 2023) [22]. We adjusted the TF-to-motif mappings to TF-to-gene mappings by mapping motifs to target genes to generate TF-gene-regulatory networks.

DrugBank:

We downloaded DrugBank's complete database (Version 1.5.8) in Jan. 2021. This database contains information about drugs, including drug approval, drug targets, drug metabolism genes, and indications. We also used and modified functions to access drug metabolism enzyme information from the drugbankR R package (version 1.5) to identify drug targets and metabolism enzymes of all drugs in the FAERS dataset.

Fisher's exact test and reporting odds ratio of FAERS database:

To determine if drug and adverse event pairs were more likely to occur in one sex, we conducted a Fisher's exact test and calculated the reporting odds ratio (ROR). We constructed contingency tables for each drug-adverse event combination for females compared to males. These tables included the following groups: A = the number of female patients with target drug-adverse event pairs, B = the number of female patients with the drug but not the same adverse event, C = the number of male patients with target drug-adverse event pairs, and D = the number of male patients with the drug but not the same adverse event. In addition, based on these contingency tables, we filtered to focus on more commonly used drugs-adverse event pairs in both sexes via the following thresholds:

- 30 cases of the drug-adverse event pair in at least one sex ($A \geq 30$ or $C \geq 30$)
- 50 cases of drug-adverse event pair across both sexes ($A+C \geq 50$)
- 1000 cases for a drug across all four groups ($A+B+C+D \geq 1000$)
- More than five adverse events in both sexes ($A > 5$ and $C > 5$).

Our approach was similar to the previous Yu et al. 2016 study [6]. We used the Benjamini-Hochberg (BH) procedure to adjust for multiple hypothesis testing. The calculated ROR from the Fisher's exact test described if females (i.e., positive ROR) or males (i.e., negative ROR) were more likely to report the drug-adverse event combination. These ROR values were log-base2 transformed (i.e., $\log_2(\text{ROR})$). A threshold of absolute $\log_2(\text{ROR})$ greater than one and the BH-adjusted p-value less than 0.05 identified sex-biased drug-adverse event pairs in the FAERS database. We determined if there were shared or different drugs and adverse events between the male- and female-biased drug-adverse event pairs via hypergeometric test for both drugs and adverse events.

Identifying SBAE-associated drug target and drug metabolism genes:

We annotated the 416 drugs identified as associated with an SBAE (i.e., SBAE-associated drugs) with their drug targets and drug metabolism enzyme genes from DrugBank [23]. To evaluate if drug targets were enriched in the drug target list of the 416 SBAE-associated drugs compared to randomly selected drugs, we performed permutation testing for all the drug targets of drugs in the FAERS database. We randomly selected the same number of drugs (i.e., 416) from FAERS and identified the number of drugs with that target, repeating the process 1,000 times. We performed a one-sample Wilcoxon signed rank test to determine if the number of SBAE-associated drugs with that drug target was higher than those for the randomly selected drugs. We applied a BH p-value adjustment. We filtered our top SBAE-associated drug targets by BH-p-value < 0.001 . To focus our downstream analysis on SBAE-associated drug targets across SBAE-associated drugs, five SBAE-associated drugs had to have that known drug target. We also applied these same processing and filtering methods to drug metabolism genes.

Sex-specific tissue gene-regulatory network construction and sex-specific community analysis:

We applied the PANDA methodology to construct sex-specific gene-regulatory networks by tissue. PANDA integrates regulatory (TF Motif mappings from DNA-motifs curated by the Glass Lab [22]), protein-protein interaction (STRING Database [24]), and qsmooth normalized gene expression profiles from one sex and tissue via the pandaR package (version 1.30.0) [21]. We compared each tissue's sex-specific network community structures via ALtered Partitions Across Community Architectures (ALPACA)'s differential modularity functionality (netZooR version 1.2.1). This algorithm determines genes and transcription factors are differentially connected between networks, in this case, between the female and male networks. We made this comparison twice: once to determine female-specific communities and once to determine male-specific communities. To determine female-specific communities, we assigned the female network as the perturbed network and the male as the baseline network. Then, to identify male-specific communities, we assigned the male network as the perturbed network and the female network as the baseline network. Along with assigning each transcription factor and gene to a network community, we used this approach to determine the differential modularity score for each node in each network. This differential modularity score describes how important a node (i.e., transcription factors and genes) is to the resulting community assignment.

Sex-specific community core genes:

Based on the differential modularity scores from our ALPACA sex-specific community results, we identified the core genes for each sex-specific community for each GTEx tissue included in our study. For each sex-specific community in a tissue, we identified the 100 genes with the highest differential modularity scores as core genes for that tissue sex-specific community based on [18]. After identifying these core genes, we conducted functional enrichment analysis via gprofiler2 (version 0.2.1) to determine enriched pathways for each sex-specific community across the GTEx tissues [25].

Drug metabolism genes' sex-specific gene-regulatory relationships:

To determine the network property differences between male and female gene-regulatory networks around drug metabolism genes, we downloaded the Kyoto Encyclopedia of Genes and Genomes (KEGG)'s drug metabolism gene list (KEGG_DRUG_METABOLISM_CYTOCHROME_P450.v2022.1.Hs.gmt) from MSigDB via Gene Set Enrichment Analysis (GSEA)'s website in Jan 2023 (<https://www.gsea-msigdb.org/gsea/msigdb/human/collections.jsp>) [26–28].

Sex-specific communities and differential modularity:

We compared the differential modularity score from the ALPACA analysis of the drug metabolism genes in both male and female gene-regulatory networks by tissue with paired Wilcoxon rank sum test with continuity correction with a Bonferroni p-value adjustment. This comparison determined if the differential modularity scores for drug metabolism genes significantly differed between the sexes across tissues. We also calculated the log₂ fold change of the differential modularity (female - male) of drug metabolism genes between the male and female networks. In addition, based on the community assignments from the ALPACA analysis, we annotated the membership of the drug metabolism genes across the sex-specific communities for each tissue.

Weighted in-degree difference:

We used the calcDegree function from the pandaR package to calculate the weighted in-degree for each drug metabolism gene for each sex-specific tissue network. Then we compared weighted in-degree between the sexes by conducting a Wilcoxon rank sum test with continuity correction applied across each tissue and then made a Bonferroni-corrected p-value adjustment [29]. We also calculated the median of the weighted in-degree difference between the male and female drug metabolism genes for each tissue.

Sex-biased edges and targeting:

We examined if genes had different proportions of sex-biased edges (i.e., predicted transcription factor and gene regulatory relationships) between the male and female liver gene-regulatory networks. We defined each targeted gene as sex-divergent (i.e., the proportion of sex-biased edges in the male- and female-biased directions is between 0.4 and 0.6), female-biased (i.e., the proportion of sex-biased edges in the female direction is greater than 0.6), or male-biased (the proportion of sex-biased edges in the male direction is greater than 0.6) as previously reported by Lopes-Ramos et al. [19].

Specific edges activator and repressor relationships:

For the liver sex-specific gene-regulatory networks, we determined the predicted regulation of the transcription factor and targeted drug metabolism genes by finding the Pearson correlation between a given transcription factor gene's expression and the targeted drug metabolism gene's expression. If the Pearson correlation was significant after Benjamini-Hochberg (BH) p-value adjustment and positive, we defined these edges as activator edges. If the Pearson correlation was significant after BH p-value adjustment and negative, we described these edges as repressor edges. If the correlation was not significant, we defined these relationships as undefined. We applied this in a sex-specific manner where we only correlated the transcription factor and target gene's expression by sex and in a non-sex-specific manner.

Once we identified these predicted regulatory relationships, we determined which relationships (i.e., edges) differed or were the same between the male and female liver gene-regulatory networks for drug metabolism genes. Then, we used functional enrichment analysis via gprofiler2 to determine enriched pathways and annotated gene sets for sex-specific relationships (i.e., male activators, male repressors, female activators, male repressors) [25]. We compared the enriched Biological Process GO terms across these sex-specific relationships by semantic similarity based on the method proposed by Wang 2007 [30], which considers the relationship of GO terms in the GO hierarchy via the GOSemSim R package (version 2.24.0) [30,31]. We used functions from rvgo (version 1.10.0) (getGoTerm, loadOrgdb, getGoSize, reduceSimMatrix) to create GO term common parent terms from the enriched pathways based on the parent term in the GO hierarchy and the Wang semantic similarity [32]. We plotted the enriched pathway results in a heatmap and clustered them using ComplexHeatmap (version 2.14.0) [33].

To determine if there are more activator- or repressor-predicted gene-regulatory relationships impacting drug metabolism genes in sex-specific networks, we determined the difference in the sum of the activator edge weights and the sum of the repressor edge weights for each sex. If this value for a drug metabolism gene is positive, there are more activator edges than repressor edges. If this value for a drug metabolism gene is negative, then more predicted repressor relationships exist. We applied a paired Wilcoxon signed rank test with continuity correction to determine if there was a difference in the targeting relationships between male and female liver gene-regulatory networks of drug metabolism genes.

Permutation testing of sex-biased gene expression and sex-biased core genes of SBAE-associated drug targets and core genes of sex-specific communities:

In a previous study with the GTEx project, Oliva et al. identified sex-biased expressed genes for 44 different tissues [17]. We downloaded the sex-biased gene expression results in March 2023 from the GTEx portal (<https://www.gtexportal.org/home/datasets>). We assessed SBAE-associated drug targets and drug metabolism enzyme genes for sex-biased gene expression across each tissue (i.e., the GTEx sex-biased gene sets). We performed permutation testing by randomly selecting 84 drug targets (the same number of SBAE-associated drug targets we identified) 1,000 times with a one-sample Wilcoxon signed rank test and a BH-multiple hypothesis test correction. We applied the same approach for the drug metabolism genes but with 71 or 64 for drug metabolism genes expressed in the liver tissue or the liver gene-regulatory networks,

respectively. We repeated this permutation approach with the core genes of the sex-specific gene-regulatory communities for both SBAE-associated drug targets and drug metabolism genes.

Results

SBAE-associated drugs are enriched for known drug metabolism genes and drug targets.

We first used the FAERS database to identify drug-adverse event pairs more likely to occur in one sex by requiring that each drug-adverse event pair have at least five cases for both sexes to ensure selection for sex-biased and not just sex-specific adverse events (i.e., where the condition occurs in one sex such as prostate cancer). Similar to previous studies with the FAERS database [6,8,10], we identified more drug-adverse event pairs with a female bias than a male bias (2132, female; 748, male) (**Figure 2A and Supplemental File 3**). When we investigated the most common SBAEs based on the number of significant drug-adverse event pairs, malignant neoplasm progression, acute kidney injury, and death were the top three male-biased adverse events. The top female-biased adverse events were alopecia, urinary tract infection, and drug hypersensitivity (**Supplemental Figures 1 & 2**). Some of these adverse events are known to have higher incidents in one sex, for example, male-biased malignant neoplasm progression and female-biased alopecia and urinary tract infection [6,10]. In accordance with previous literature using FAERS and other independent databases and studies, we identified drugs for both male-biased and female-biased drug-adverse event pairs that were identified as sex-biased, such as warfarin [34], cholecalciferol [35], prednisone [36], methotrexate [37], and denosumab [38], which were in the top three male and female-biased adverse events (**Supplemental Figure 3 & 4**).

Across the 2,880 significant sex-biased drug-adverse event pairs, we identified 610 male- or female-biased adverse events. Of those, 77 were shared by males and females, which was not a significant overlap (p -value = 0.293085, hypergeometric test) (**Figure 2B**). However, there was a significant enrichment of shared SBAE-associated drugs. We found that 208 of the 416 unique SBAE-associated drugs from those drug-adverse event pairs were significantly associated with male and female drug-adverse event pairs (p -value= 2.524481e-11, hypergeometric test) (**Figure 2C**). When we clustered the 50 most common drugs and the 50 most common adverse events from those 2,880 significant drug adverse-event pairs by their logROR, we found they clustered most strongly based on the SBAE (**Supplemental Figure 5**). This suggests that particular adverse events are more susceptible to SBAEs compared to particular drug mechanisms.

After identifying these sex-biased drug-adverse event pairs, we determined drug metabolism genes and targets enriched in the known drug metabolism enzymes and targets of SBAE-associated drugs via permutation testing of a matched number of random drugs. From this, we identified 32 known drug metabolism genes enriched in the known targets of SBAE-associated drugs (**Figure 2D**). The most prevalent known drug metabolism enzyme across our identified SBAE-associated drugs, CYP3A4, is also the most prevalent drug metabolism enzyme for FDA-approved drugs overall, as an estimated 50% of FDA-approved drugs are metabolized by this enzyme [39]. For drug targets, we identified 84 drug targets enriched in the known drug targets of our identified SBAE-associated drugs compared to random drug selection (**Figure 2E**). Two of the top three SBAE-associated drug targets were adrenergic receptors (i.e., *ADRA1A* & *ADRA2A*). These receptors are already known to have sex differences in locus coeruleus (LC)-norepinephrine (NE) arousal activity in different brain regions due to higher estradiol presence in females compared to males, which has been hypothesized to increase norepinephrine (NE) arousal in females [40].




Figure 2: Sex-biased drug-adverse event pairs in FAERS. A) Volcano plot of the log-transformed reporting odds ratio (ROR) and the negative log-transformed Benjamini-Hochberg p-values from Fisher's exact test of overlap of drug and SBAEs. **B)** Overlap of drugs from male- and female-biased drug-adverse event pairs. **C)** Overlap of adverse events from male- and female-biased drug-adverse event pairs.

The gene-regulatory network neighborhoods around drug metabolism genes differ between males and females in the liver.

Previous studies have identified that many drug metabolism genes have sex-biased gene expression in the liver [14–17], so we chose to investigate sex-specific liver gene-regulatory networks to determine if there are potential gene regulation differences of drug metabolism genes between males and females in the liver. Therefore, we constructed sex-specific liver gene-regulatory networks via the PANDA network methodology, representing the predicted regulatory relationship between transcription factors and target genes [41]. To investigate the immediate node neighbors (i.e., the network neighborhoods), we calculated the weighted in-degree (describes the magnitude of the predicted transcription factor regulation of a gene) of drug metabolism genes (as annotated by KEGG, $n = 64$) in the sex-specific liver networks [27]. We found that drug metabolism genes had a higher weighted in-degree (i.e., more targeted) in the female network compared to the male network (median of the degree difference of drug metabolism genes = 34.15683) (**Figure 3A**). To confirm if this relationship is specific to drug metabolism genes, we compared the degree difference of drug metabolism genes to other genes in these liver networks. We found a significant difference via a Wilcoxon rank sum test with continuity correction ($W = 663550$, $p\text{-value} = 1.48 \times 10^{-8}$) (**Figure 3A**). Additionally, we determined that this relationship is specific to only a few tissues by comparing male and female PANDA networks in 42 of the other GTEx tissues and applying the same Wilcoxon test followed by a Bonferroni correction (**Figure 3B**). Six other tissues besides the liver (“Brain Hypothalamus,” “Artery Coronary,” “Brain Anterior Cingulate Cortex [BA24],” “Heart Left Ventricle,” “Brain Nucleus Accumbens [basal ganglia],” and “Small Intestine-Terminal Ileum”) had more transcription factor targeting in female networks. In comparison, three other tissues (“Pancreas,” “Minor Salivary Gland,” and “Artery Aorta”) had more transcription factor targeting in male networks. However, the liver is the most significantly different tissue based on the Wilcoxon rank sum test with continuity correction with a Bonferroni correction (**Figure 3B**), and our results indicate that more transcription factors are predicted to regulate drug metabolism in the female liver gene-regulatory network compared to the male.

We were also interested in determining groups of transcription factors and genes that are more interconnected in their edge relationships in one sex-specific network than the other sex-specific network (i.e., sex-specific communities) in the liver. We identified eight female-specific communities and 11 male-specific communities. When we investigated which communities contained the most drug metabolism genes, we determined that female community number two included 41 of the 64 drug metabolism genes, and the other drug metabolism genes were contained in four other female-specific communities (**Supplemental Figure 6**). However, in the male network, we found that drug metabolism genes were divided between two male-specific communities (communities four and five), which contained 19 and 17 of the 64 drug metabolism genes, respectively (**Supplemental Figure 6**). The eight other male-specific communities contained the remaining 28 drug metabolism genes. We conducted functional enrichment analysis on the core genes (core genes have the highest differential modularity score, a score used to determine the sex-specific communities) of all the liver sex-specific communities. Several transcriptional pathways from KEGG and Reactome were similar between the female and male drug metabolism enzymes communities, such as the RUNX protein-associated pathways and nuclear receptor transcription pathway (i.e., liver female-specific community number two and male-specific communities numbers four and five). However, male-specific community number four had several pathways associated with FOXO transcription activities (i.e., “FOXO-mediated transcription of cell death genes,” “FOXO-mediated transcription,” “Regulation of FOXO transcriptional activity by acetylation,” “Regulation of localization of FOXO transcription factors,” and “FOXO-mediated transcription of cell cycle genes”) that were

not shared with female-specific community number two and male-specific community five (i.e., the sex-specific liver communities with the most drug metabolism genes). Interestingly, previous aging studies have found that sex-dependent single nucleotide polymorphisms (SNPs) in *FOXO1A* (a protein important for regulating energy metabolism in the liver) are associated with increased longevity in females [42,43] (**Supplemental File 4**).

For each community, we found differing transcription factor and gene differential modularity scores, which describe how important that transcription factor or gene is to community integrity (i.e., if the node was removed, would the community structure still be present). We found that four drug metabolism genes, *CYP2E1*, *CYP3A43*, *GSTM4*, and *UGT2B17*, were also core genes in the male-specific liver communities (i.e., these genes had the highest differential modularity score). There was no significant enrichment of core genes in the drug metabolism gene set compared to randomly selected genes for sex-biased, female-biased, and male-biased liver core gene lists (**Supplemental Figure 7**). Overall, we found that drug metabolism genes have higher differential modularity (i.e., community integrity importance) in the male network compared to the female network (log2 fold change of female vs. male = -2.47633758, paired Wilcoxon signed rank test: $V= 289$, $p\text{-value} = 5.19 \times 10^{-7}$) (**Figure 3C**). When we investigated differential modularity across all the tissues, this relationship was specific to the “Liver,” “Brain Amygdala,” and “Small Intestine - Terminal Ileum” tissues. This differential modularity score indicates that drug metabolism genes in the male liver gene-regulatory network are essential to sex-specific communities but are not targeted as highly as the drug metabolism genes in the female liver gene-regulatory network.




Figure 3: The neighborhood of sex-specific liver gene-regulatory networks around drug metabolism genes. **A**) Degree difference distributions of the sex-specific liver networks for drug metabolism genes compared to all other genes. **B**) Bar plot of the negative log-transformed p-value from the Wilcoxon test with colored bars showing the degree difference of drug metabolism genes between female and male sex-specific networks by tissue. **C**) Violin plot of the differential modularity score of drug metabolism genes in the male and female sex-specific communities. **D**) Bar plot of the negative log-transformed p-value from the paired Wilcoxon test with colored bars showing the log₂ fold change by tissue. For the bar plots, purple is a higher degree (B) or differential modularity (D) in female networks, and teal is a higher degree or differential modularity in male networks. The black dotted line is the p-value cutoff for the Bonferroni hypothesis test correction.

Liver sex-specific networks have different drug metabolism gene-regulatory relationships.

We next investigated the network edges representing the predicted regulatory relationship between a given transcription factor-gene pair that involved a drug metabolism gene (**Figure 4A**). Across all the known drug metabolism enzyme genes, we identified three female-biased targeted genes, *GSTO2*, *CYP2D6*, and *ALDH3A1* (i.e., the proportion of sex-biased edges in the female direction was greater than 0.6), and four male-biased targeted genes, *MAOA*, *AOX1*, *MGST1*, and *ALDH3B1* (i.e., the proportion of sex-biased edges in

the male direction was greater than 0.6). When we compared the sex-biased targeted genes and the SBAE-associated drug metabolism enzymes, both *CYP2D6* and *MAOA* were drug metabolism genes of SBAE-associated drugs.

We calculated the Pearson correlation between transcription factors and drug metabolism genes and significance to identify types of potential regulatory relationships (i.e., BH p-value < 0.05). A significant positive correlation was an activator relationship, and a significant negative correlation was a repressor relationship. About 52% of these edge relationships were unique to one sex (**Figure 4B**). Interestingly, the only edge to have an opposite relationship between males and females was *ONECUT1_GSTM3*. While it was predicted to have an activator relationship in the female liver network ($\rho = 0.3511445$), it was predicted to have a relatively weaker repressor relationship in the male liver network ($\rho = -0.1877166$). Altogether, these results highlight that 1453 of the 2801 edges (~51.87%) involving drug metabolism genes were unique to either sex. However, when the edges were present in both sexes, they had the same edge relationship (i.e., activator or repressor). Only 1 of the 1348 shared edges (~0.07%) had an opposite relationship between males and females.

Given that about half of the drug metabolism gene edges were unique to one sex, we determined which GO Biological Processes were enriched between the distinctive male and female edges. We applied semantic similarity analysis to determine how similar the enriched GO terms were between the female and male activator and repressor edges and the common parent GO term of all the enriched GO terms (**Figure 4C** and **Supplemental File 5**). For all the unique sex-specific edges, “regulation of transcription by RNA polymerase II” (unsurprising given the abundance of transcription factors due to the examination of gene-regulatory relationships) and “lipid metabolic process” common parent GO terms were enriched. Male activator and repressor gene sets had more GO terms enriched for the following common parent GO terms than the female activator and repressor gene sets: “T-cell activation,” “nervous system development,” “glucose homeostasis,” “cellular response to lipopolysaccharide,” “cell differentiation,” “female pregnancy,” “positive regulation of cell population proliferation,” and “response to xenobiotic stimulus”. The parent term “female pregnancy,” which had more enriched GO terms with the male repressor and activator edges, included the following GO terms that relate to reproduction: “female courtship behavior,” “reproductive process,” “reproduction,” “developmental process involved in reproduction,” “multi-organism reproductive process,” and “female pregnancy” (**Supplemental File 5**). Overall, the number of male-biased common parent GO term groups (i.e., 8 of 10 common parent GO terms across all enriched pathways) indicates that liver male-specific edges of drug metabolism genes are potentially involved in more biological programs than female-specific edges.

For each drug metabolism enzyme gene, we determined if it had more activator or repressor targeting in the sex-specific networks (similar to the degree difference analysis in **Figure 3A**). In the female-specific liver network, we found 30 activator-targeted drug metabolism genes (i.e., a positive difference of activator and repressor edges of drug metabolism genes in the sex-specific liver networks) and 33 repressor-targeted drug metabolism genes (i.e., a negative difference of activator and repressor edges of drug metabolism genes in the sex-specific liver networks) (**Figure 4D**). However, in the male-specific liver network, we identified 24 activator-targeted and 39 repressor-targeted drug metabolism genes (**Figure 4D**). In addition, 16 drug metabolism genes had opposing targeting relationships between males and females. *GSTM1*, *UGT1A8*, *CYP1A2*, *ADH1B*, and *ADH1A* were more activator-targeted in the male liver network, while they were more repressor-targeted in the female liver network. However, *ADH4*, *CYP2C19*, *CYP2D6*, *FMO3*, *FMO5*, *GSTA1*, *GSTK1*, *GSTZ1*, *UGT2B10*, *UGT2B11*, and *UGT2B7* were more activator-targeted in the female liver network and more repressor-targeted in the male liver network. We determined that the activator and repressor targeting of the drug metabolism genes in males and females differed (Wilcoxon signed rank test with continuity correction, $V = 1504$, p-value = 0.0006932). Five of the 11 differentially targeted drug metabolism genes were SBAE-associated drug metabolism enzyme genes, which might explain some SBAEs, including those associated with *CYP2D6*, which metabolizes 25% of drugs currently on the market (**Figure 2D**) [44].




Figure 4: Predicted gene-regulatory relationships of drug metabolism genes in the sex-specific networks of the liver differ. A) Heatmap of the male and female associated liver gene-regulatory edges of drug metabolism genes (x-axis) and transcription factors (y-axis). The coloring on the heatmap indicates the

network(s) where an edge was present. The y-axis is annotated with the transcription factors with the most male or female edges. **B)** Upset plot showing the intersection of activator and repressor transcription factor-gene edges in the female and male-specific liver networks. **C)** A dendrogram of the enriched GO Biological Process terms of unique female and male activator/repressor edges. The “Common Parent GO Term[s]” clustering and selection were based on Wang's semantic similarity. **D)** A heatmap of the difference in activator and repressor edges of drug metabolism genes in the sex-specific liver networks.

SBAE-associated drug targets were more likely to have sex-biased gene expression and be core genes in sex-specific gene-regulatory networks than other drug targets.

Building on previously identified sex-biased gene expression in GTEx, we determined if the SBAE-associated drug targets we identified above also had sex-biased gene expression (**Figure 5A**) [17]. We found that 52 of the 84 (~ 62%) SBAE-associated drug targets had sex-biased gene expression in at least one tissue (29 had higher male gene expression in at least one tissue, and 35 had higher female gene expression in at least one tissue). We conducted permutation testing to determine if our identified SBAE-associated drug targets were more likely to have sex-biased gene expression than random sets of drug targets (**Supplemental Figure 8**). Across the GTEx tissues, we found that our identified SBAE-associated drug targets were significantly enriched (BH-adjusted p-value < 0.05) for sex-biased gene expression compared to randomly selected drug targets with respect to both female-biased (24 of 44 tissues) and male-biased (7 of 44 tissues) gene expression gene sets. The enrichment of SBAE-associated drug targets with sex-biased gene expression indicates that SBAEs could be due to drugs perturbing genes with sex-biased gene expression.

Furthermore, we explored *ADRA1A*, *DRD1*, and *ADRA2C*, the top three male-biased SBAE-associated drug targets based on the Euclidean distance clustering of sex-biased gene expression across tissues (**Figure 5A**) [33]. 26, 13, and 18 SBAE-associated drugs had *ADRA1A*, *DRD1*, and *ADRA2C* as a drug target, respectively. Both *ADRA1A* and *ADRA2C* are adrenergic receptors and are important for locus coeruleus (LC)-norepinephrine (NE) arousal activity [40]. While the adrenergic α 2C-receptors (*ADRA2C*) have been shown to influence aggression behaviors in male mice, neither study investigated female mice in their study design [45,46]. Of the 52 male-biased drug-adverse event pairs with SBAE-associated drugs with *ADRA1A* as a drug target, 20 male-biased adverse events were related to psychiatric disorders (**Supplemental Figure 9A**). In contrast, only one of the 126 female-biased *ADRA1A* adverse events was a psychiatric disorder (**Supplemental Figure 9B**). The highest male-biased adverse event preferred term was aggression which has the system organ class assignment of psychiatric disorder (**Supplemental Figure 9C**). *ADRA1A* had male-biased gene expression in five GTEx brain regions compared to females (“Brain Substantia Nigra,” “Brain Nucleus Accumbens Basal Ganglia,” “Brain Putamen Basal Ganglia,” “Brain Amygdala,” and “Brain Spinal Cord Cervical c.1”) (**Figure 5A**). Additionally, 18 SBAE-associated drugs had *ADRA2C* as a drug target. 17 of 31 male-biased drug-adverse event pairs of SBAE-associated drugs with *ADRA2C* as a drug target were male-biased for psychiatric disorder adverse events (**Supplemental Figure 10A**). In contrast, only one of the 63 female-biased adverse events was a psychiatric disorder (**Supplemental Figure 10B**). Aggression was the highest preferred term for male-biased drug-adverse event pairs with *ADRA2C* as a drug target (**Supplemental Figure 10C**). This gene's expression is only sex-biased in the hypothalamus (male-biased) (**Figure 5A**). Lastly, *DRD1*, a D1 dopamine receptor-coding gene, is the most abundant dopamine receptor subtype in the central nervous system [47]. 12 of the 21 male-biased drug-adverse event pairs of SBAE-associated drugs with *DRD1* as a drug target also had male-biased psychiatric disorder adverse events (**Supplemental Figure 11A**). However, only one female-biased psychiatric disorder adverse event was associated with a drug that targets *DRD1* (**Supplemental Figure 11B**). However, *DRD1* does not have sex-biased gene expression in GTEx brain tissue RNA-Seq data (**Figure 5A**). Additionally, aggression had three male-biased adverse events, the highest along with hallucination, for SBAE-associated drugs with *DRD1* as a drug target (**Supplemental Figure 11C**). *DRD1* genetic variation and gene expression in different brain regions has been implicated with aggression, cognitive impulsivity, and psychosis [48–52]. It is currently

unclear from the literature if there is documentation of sex-biased *DRD1* gene expression affecting aggressive phenotypes.

The top three female-biased drug targets with the highest number of tissues with female-biased gene expression were *FCGR2B*, *AR*, and *CACNA1S* [33]. 6, 28, and 6 SBAE-associated drugs had *FCGR2B*, *AR*, and *CACNA1S* as drug targets, respectively. 7 of the 45 female-biased drug-adverse event pairs with SBAE-associated drugs targeting *FCGR2B* had female-biased adverse events related to general disorders and administration site conditions, and six female-biased drug-adverse event pairs were infections and infestations (**Supplemental Figure 12**). *FCGR2B* is expressed by many immune cells, and previous literature identified that macrophages have higher *Fcgr2b* expression in female mice [53,54]. In addition, many SNPs of *FCGR2B* are associated with an increased risk of systemic lupus erythematosus, an autoimmune disease known to be more prevalent in females than males [54–56]. *AR* is the androgen receptor that interacts with androgens, including testosterone, and this receptor is important for sex differences in neural circuitry and metabolism [57]. Its expression was female-biased in 26 tissues, including 9 of 13 brain regions (**Figure 5A**). However, its expression was also male-biased in the tibial nerve and the subcutaneous adipose tissue (**Figure 5A**). While this gene's expression was female-biased across 26 GTEx tissues, perturbing *AR* is associated with both male- and female-biased adverse events related to psychiatric disorders and nervous system adverse events, respectively (**Supplemental Figure 13A & B**). 11 of the 110 female drug-adverse event pairs we identified with *AR* as a drug target had female-biased nervous system adverse events, and 11 of the 60 male drug-adverse event pairs were related to male-biased psychiatric disorders (**Supplemental Figure 13A & B**). Lastly, *CACNA1S* has female-biased expression in 11 of the 13 GTEx brain regions (**Figure 5A**), and 9 of the 58 female-biased drug-adverse event pairs with *CACNA1S* as a drug target were related to the nervous system (the second highest number of female-biased drug-adverse events) (**Supplemental Figure 14**). Overall, these cases highlight a potential connection between a drug target's sex-biased gene expression and their most common adverse events.

We also hypothesized that SBAEs might be due to drug targets that are core genes of sex-specific communities. We built sex-specific tissue networks for 43 different tissues based on the gene expression data from the GTEx project. We identified sex-specific communities within each tissue using the same process for the liver gene-regulatory network analysis above. We selected 100 core genes for each sex-specific community from the top 100 highest differential modularity score genes in each sex-specific community. In total, 58 of the 84 (~ 69%) SBAE-associated drug targets were a core gene of a sex-specific gene-regulatory network in at least one tissue (**Figure 5B**). 41 of the 84 (~ 49%) SBAE-associated drug targets were male core genes in at least one tissue, and 43 of the 84 (~ 51%) drug targets were female core genes in at least one tissue. In total, SBAE-associated drug targets were enriched for female sex-specific community core genes in 34 tissues and for male sex-specific community core genes in 32 tissues (permutation testing with BH-p-value <0.05) (**Supplemental Figure 15**). We found that the nuclear receptors *PPARA*, *PGR*, *PPARG*, *AR*, and *NR3C1*, known to be regulated by hormone signaling (including sex hormones [58]), were drug targets and core genes to more than half of the tissues analyzed [58]. Additionally, *PPARA* is not differentially expressed between males and females in the GTEx dataset, while the other core genes had sex-biased gene expression in at least one tissue. We found one study where a PPAR α agonist treatment before a stroke was neuroprotective in male mice but not females, suggesting that perturbation of PPAR α might be sex-dependent [59]. Therefore, *PPARA* is an example of a gene that was a sex-biased gene-regulatory core gene without sex-biased gene expression, but where there was literature evidence of a sex-dependent PPAR α agonist treatment drug response.

Overall, we found that 71 of the 84 (~ 85%) drug targets had either sex-biased gene expression (~ 62%) or high differential modularity in sex-specific communities (~ 49%) (**Supplemental File 6**). 39 of 71 drug targets overlapped between the sex-biased gene expression list and the core gene list, and 13 and 19 drug targets were only identified by sex-biased gene expression or core genes, respectively. We found that 194 of the 389 (~ 50%) SBAE-associated drugs we identified had at least one of the 71 drug targets we identified as

having sex-biased gene expressions or core genes of sex-specific communities. These SBAE-associated drug target sex-biased differences in gene expression and gene-regulatory networks support our hypothesis that SBAE-associated drug targets are enriched for sex differences in gene expression.





Figure 5: Most SBAE-associated drug targets have sex-biased gene expression or are sex-specific community core genes. A) Sex-biased gene expression of SBAE-associated drug targets across tissues. **B)** SBAE-associated drug targets were sex-specific gene-regulatory network core genes across tissues. Euclidean distance clustering with ComplexHeatmap's complete algorithm was used for both heatmaps.

Discussion

Prior pharmacovigilance studies have identified SBAEs, and multiple studies have investigated sex differences in gene expression and gene-regulatory networks, implicating their role in drug metabolism and response [6–11,14,18,20]. In this study, we sought to identify if there are sex differences in gene expression and the gene-regulatory networks of the drug targets of SBAE-associated drugs. We first identified 32 drug metabolism enzymes and 84 drug targets enriched for SBAE-associated drugs. The liver gene-regulatory neighborhood and edges differed for drug metabolism enzymes between male and female gene-regulatory networks. Additionally, we found that SBAE-associated drug targets were more likely to be sex-biased expressed genes and the core genes of sex-specific gene-regulatory communities than randomly selected drug targets. Our findings support the hypothesis that some SBAEs may be due to drugs perturbing genes with sex-biased gene expression or gene-regulatory network properties.

Like previous pharmacovigilance studies with similar methods, we identified more than twice as many female SBAEs as male SBAEs [6,8,10]. Additionally, we identified 610 male- or female-biased adverse events, and the top three male- and female-biased drugs associated with SBAEs were also identified previously [34–38]. These findings are clinically relevant. For example, the second most common male-biased adverse event we identified was acute kidney injury (AKI). It is known that drug-induced AKI is a common cause of AKI, accounting for approximately 19% of AKI in hospital settings [60,61]. We also identified drug hypersensitivity as female-biased, supported by previous reviews of pharmacovigilance studies [62] and evidence suggesting multifactorial explanations for why females are more likely to have drug hypersensitivity, including potential genetic and epigenetic causes [63]. Our results highlight the need for more research investigating causal relationships between adverse events, drug mechanisms, and sex differences.

In this study, we also expanded upon previous studies examining sex differences in drug metabolism genes in the liver. *CYP3A4* has higher gene expression, protein expression, and activity in females and was the most common drug metabolism enzyme across the SBAE-associated drugs we identified [64]. We also found that *CYP3A43* was a male core gene. In addition, two of the SBAE-associated drug targets, *CYP2D6* and *MAOA*, were female- and male-biased targeted in the sex-specific liver gene-regulatory networks. While *MAOA* was the 24th most common SBAE-associated drug metabolism gene, *CYP2D6* was the second most common SBAE-associated drug metabolism gene, and it was estimated 25% of drugs on the market use the *CYP2D6* enzyme [44]. We identified two common drug metabolism enzymes enriched in SBAE-associated drugs with sex differences in liver gene-regulatory networks.

We further applied gene-regulatory network methodology to explore if there are predicted sex differences in gene regulation in the liver. We found that drug metabolism genes in the liver female gene-regulatory network are targeted more than in the male network via the weighted in-degree difference. On the other hand, drug metabolism genes in the liver male gene-regulatory network had a higher differential modularity than in the female gene-regulatory network indicating that they are more important for sex-specific network community integrity. In addition, the unique male liver network edges were involved in multiple biological processes, including “T-cell activation,” “nervous system development,” and “glucose homeostasis.” Our results support a potential female neighborhood structure where drug metabolism genes are more targeted than in the male liver network, and the transcription factors that regulate drug metabolism genes are involved in fewer biological programs than in the male network. This network structure further underscores that the influence of sex is complex for liver drug metabolism gene expression. For example, multiple biological processes utilize the same transcription factors as drug metabolism genes in the male-specific liver network. One common parent GO term from our GO semantic similarity analysis of the unique sex-specific edges of the

drug metabolism genes was “glucose homeostasis.” Male repressor and activator edges were enriched for “glucose homeostasis,” “carbohydrate homeostasis,” “regulation of hormone levels,” “cellular glucose homeostasis,” “homeostasis of number of cells,” and “cellular response to glucose stimulus.” A prior study found that long-term exposure to abnormal glucose levels affected the activity of drug metabolism enzymes in primary hepatocytes, but unfortunately, it did not state the donor sex of the cells used in the experiment or discuss the impact of sex [65]. Future studies are needed to delineate the role of gene-regulatory sex differences in drug metabolism to determine the relative contribution of gene expression, protein expression, and protein activity to SBAE.

In this study, we sought to evaluate our hypothesis that drugs associated with SBAEs are perturbing sex-biased gene expression and gene-regulatory networks. The 84 enriched SBAE-associated drug target genes we identified were more likely to be expressed in a sex-biased manner and to be core genes than other drug targets across several tissues. In addition, we found that some of the SBAE-associated drug targets with sex-biased gene expression were associated with a common adverse event and associated sex-biased gene expression in the tissue manifesting that adverse event. For example, *ADRA1A* and *ADRA2C* were both associated with the male-biased adverse event of aggression. We found that these genes have higher expression in many brain regions in males than in females. However, we identified other SBAE-associated drug targets with more complicated expression and network patterns. For example, *AR*, which codes for the androgen receptor, is known to be influenced by the sex hormone testosterone, which is dynamically secreted over hours and decades [66]. *AR* was among the top three female-biased expressed genes and sex-biased core genes in all 43 tissues (**Figure 5**). We found that it had common female-biased adverse events of nervous system disorders and male-biased adverse events of psychiatric disorders, suggesting *AR* may contribute to different SBAEs for each sex.

There are some limitations to the current study. First, these results are associations and not causal relationships, so future studies are needed to investigate their causality. We have provided our computational workflows and complete results to facilitate their use as a resource for future studies. Also, we acknowledge that FAERS is based on case reports susceptible to reporting biases and that GTEx samples are skewed toward male subjects. Additionally, we found that RIN score and ischemic time are potentially confounding variables in the GTEx gene expression data. This technical variation could not be incorporated into the PANDA methodology. Still, the sex-biased gene sets from Oliva et al. included RIN score and ischemic time as covariates in their analyses [17]. As we previously reviewed [4], other pharmacokinetic, pharmacodynamic, biological, and environmental factors can influence drug response in combination with sex, such as solubility of the drug, body fat percentage, age, ancestry, and diet. Another potential complexity of SBAEs could be due to disruption in one tissue affecting multiple tissues or multiple tissues being disrupted. These potential complexities were not explored in depth in this study.

Lastly, one critical limitation of this study is that we relied on bulk tissue RNA-Seq profiles from GTEx. With the invention of single-cell and spatial sequencing technology, the research community has determined gene expression differences between cell populations within a tissue sample [67–69]. For example, single-cell technology was recently used to detect sex-biased gene expression and gene-regulatory networks in mouse brain and heart tissues [70]. Concerning our study, for example, because *FCGR2B* is associated with the immune system, which was difficult to investigate with bulk gene expression profiles, other literature sources were added to help clarify our association of female-biased infections and infestations adverse events and *FCGR2B* female-bias expression in immune cells [53–56]. Another limitation of bulk tissue profiles was highlighted by tissues with multiple tissue regions sequenced by GTEx, like the brain. Because of this, we could associate more neurological and psychiatric disorder adverse events with drug targets than other tissues and adverse events. Therefore, future studies using a similar methodology applied to additional tissue subregions and single-cell profiles, particularly for organs involved in drug metabolism like the kidney and liver, are critical.

Perspectives and significance

We conducted this study to investigate the gene regulatory landscape of SBAEs and the drugs that are associated with them. We identified 32 drug metabolism enzymes and 84 drug targets enriched in the known drug targets of the drugs associated with SBAEs. We found that these drug targets were enriched for genes with sex-biased gene expression and network properties, such as being core genes of sex-specific network communities. While future studies are required to determine the causality of these associations, the SBAE-associated drug metabolism enzymes and drug targets may also be useful for predicting SBAE or drug repurposing prioritization. We highlight possible future studies as a consequence of the results of this study, further emphasizing that improving SBAE is a community effort. We also provide our computational workflows and unfiltered results as a resource for the community.


Conclusions

Here, we used data mining and network approaches to investigate not only the gene expression of both drug metabolism genes and drug targets of drugs associated with SBAEs but also examined network properties of sex- and tissue-specific gene-regulatory networks. While previous studies have focused on drug metabolism enzymes, we also investigated the known drug targets of SBAE-associated drugs. Overall, we found supporting evidence that SBAEs could be caused in part by sex differences in drug metabolism enzyme and drug target gene expression and gene-regulatory network properties. These results are a valuable resource for future studies determining SBAE mechanisms to predict and prevent SBAEs and for sex-aware drug development and repurposing.


Abbreviations

- SBAEs - Sex-biased adverse events
- FDA - U.S. Food and Drug Administration
- FAERS - FDA's Adverse Event Reporting System
- WHO - World Health Organization
- COVID-19 - coronavirus disease of 2019
- GTEx - Genotype-Tissue Expression project
- TCGA - The Cancer Genome Atlas
- GO - Gene Ontology
- KEGG - Kyoto Encyclopedia of Genes and Genomes
- MedDRA - Medical Dictionary for Regulatory Activities
- PANDA - Passing Attributes between Networks for Data Assimilation
- ALPACA - ALtered Partitions Across Community Architectures
- PCA - principal component analysis
- ROR - reporting odds ratio
- BH - Benjamini-Hochberg
- logROR- log reporting odds ratio
- SNPs - Single nucleotide polymorphisms
- AKI - acute kidney injury


Supplemental Figures




Supplemental Figure 1: Barplot of the top 30 female-biased adverse events based on the number of drugs with an adverse event.




Supplemental Figure 2: Barplot of the top 30 male-biased adverse events based on the number of drugs with an adverse event.




Supplemental Figure 3: Barplot of the top 30 drugs based on the number of female-biased adverse events associated with the drug.




Supplemental Figure 4: Barplot of the top 30 drugs based on the number of male-biased adverse events associated with the drug.




Supplemental Figure 5: Heatmap of the logROR of the 50 most common drugs (x-axis) and adverse events (y-axis) for both sexes. Purple logROR is female-biased and Teal logROR is male-bias.




Supplemental Figure 6: Bar plots of the number of drug metabolism genes in the sex-specific communities of the liver for **A)** female and **B)** male.




Supplemental Figure 7: We performed a one-tailed Wilcoxon test to determine if the number of core genes selected for drug metabolism was higher than for the randomly selected genes for **A**) Sex-biased liver core gene (p-value = 1). **B**) male-specific liver core genes (p-value = 0.9910552) **C**) female-specific liver core genes (p-value = 1).




Supplemental Figure 8: Permutation results for the SBAE-associated drug targets' enrichment of sex-biased expressed genes. A) Bar plot of the female-biased sex-biased gene expression gene sets by tissue with the x-axis being the fraction of SBAE-associated drug targets with female-biased gene expression for the tissue and the number of drug targets with sex-biased gene expression. **B)** Bar plot of the male-biased sex-biased gene expression gene sets by tissue with the x-axis being the fraction of SBAE-associated drug targets with male-biased gene expression for the tissue and the number of drug targets with sex-biased expression. Permutation testing was conducted by randomly selecting either 84 drug targets genes 1,000 times with a one-tailed Wilcoxon test and with BH-multiple hypothesis test correction ($\alpha = 0.05$).




Supplemental Figure 9: Drug target *ADRA1A*'s drug-adverse event plots. A) A bar plot of the number of male-biased drug-adverse event pairs with a drug with *ADRA1A* as drug target for each System Organ Class (SOC) adverse event term. **B)** A bar plot of the number of male-biased drug-adverse event pairs with a drug with *ADRA1A* as drug target for each Preferred Term (PT) adverse event term. **C)** A bar plot of the number of female-biased drug-adverse event pairs with a drug with *ADRA1A* as drug target for each System Organ Class (SOC) adverse event term.




Supplemental Figure 10: Drug target *ADRA1C*'s drug-adverse event plots. A) A bar plot of the number of male-biased drug-adverse event pairs with a drug with *ADRA1C* as drug target for each System Organ Class (SOC) adverse event term. **B)** A bar plot of the number of male-biased drug-adverse event pairs with a drug with *ADRA1C* as drug target for each Preferred Term (PT) adverse event term. **C)** A bar plot of the number of female-biased drug-adverse event pairs with a drug with *ADRA1C* as drug target for each System Organ Class (SOC) adverse event term.




Supplemental Figure 11: Drug target *DRD1*'s drug-adverse event plots. A) A bar plot of the number of male-biased drug-adverse event pairs with a drug with *DRD1* as drug target for each System Organ Class (SOC) adverse event term. **B)** A bar plot of the number of male-biased drug-adverse event pairs with a drug with *DRD1* as drug target for each Preferred Term (PT) adverse event term. **C)** A bar plot of the number of female-biased drug-adverse event pairs with a drug with *DRD1* as drug target for each System Organ Class (SOC) adverse event term.




Supplemental Figure 12: A bar plot of the number of female-biased drug-adverse event pairs with a drug with *FCGR3B* as drug target for each System Organ Class (SOC) adverse event term.



Supplemental Figure 13: Drug target AR's drug-adverse event plots. A) A bar plot of the number of female-biased drug-adverse event pairs with a drug with AR as drug target for each System Organ Class (SOC) adverse event term. **B)** A bar plot of the number of male-biased drug-adverse event pairs with a drug with AR as drug target for each System Organ Class (SOC) adverse event term.



Supplemental Figure 14: A bar plot of the number of female-biased drug-adverse event pairs with a drug with *CACNA1S* as drug target for each System Organ Class (SOC) adverse event term.



Supplemental Figure 15: Permutation results for the SBAE-associated drug targets' enrichment of sex-specific network core genes. A) Bar plot of the female-specific network core gene gene sets by tissue with the x-axis being the fraction of SBAE-associated drug targets with female-specific network core genes for the tissue and the number of drug targets that are female-specific network core genes. **B)** Bar plot of the male-specific network core gene gene sets by tissue with the x-axis being the fraction of SBAE-associated drug targets with male-specific network core genes for the tissue and the number of drug targets that are male-specific network core genes. Permutation testing was conducted by randomly selecting either 84 drug targets genes 1,000 times with a one-tailed Wilcoxon test and with BH-multiple hypothesis test correction ($\alpha = 0.05$).

References

1. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. *JAMA*. 2016 Nov 22;316(20):2115–25.
2. Medication Safety Basics [Internet]. 2022 [cited 2023 Apr 28]. Available from: <https://www.cdc.gov/medicationsafety/basics.html>
3. Office of the Commissioner. What is a Serious Adverse Event? [Internet]. [cited 2021 Dec 8]. Available from: <https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event>
4. Fisher JL, Jones EF, Flanary VL, Williams AS, Ramsey EJ, Lasseigne BN. Considerations and challenges for sex-aware drug repurposing. *Biol Sex Differ*. 2022 Mar;13(1):13.
5. Carey JL, Nader N, Chai PR, Carreiro S, Griswold MK, Boyle KL. Drugs and Medical Devices: Adverse Events and the Impact on Women's Health. *Clin Ther*. 2017 Jan;39(1):10–22.
6. Yu Y, Chen J, Li D, Wang L, Wang W, Liu H. Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events. *Sci Rep*. 2016 Apr 22;6:24955.
7. Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a century. *EClinicalMedicine*. 2019 Dec;17:100188.
8. Zhang X, Sumathipala M, Zitnik M. Population-scale identification of differential adverse events before and during a pandemic. *Nature Computational Science*. 2021 Oct 5;1–12.
9. Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, et al. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. *J Clin Oncol*. 2022 May 1;40(13):1474–86.
10. Chandak P, Tatonetti NP. Using Machine Learning to Identify Adverse Drug Effects Posing Increased Risk to Women. *Patterns (N Y)* [Internet]. 2020 Oct 9;1(7). Available from: <http://dx.doi.org/10.1016/j.patter.2020.100108>
11. Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. *Biol Sex Differ*. 2020 Jun 5;11(1):32.
12. Islam MM, Iqbal U, Walther BA, Nguyen PA, Li YCJ, Dubey NK, et al. Gender-based personalized pharmacotherapy: a systematic review. *Arch Gynecol Obstet*. 2017 Jun;295(6):1305–17.
13. Moyer AM, Matey ET, Miller VM. Individualized medicine: Sex, hormones, genetics, and adverse drug reactions. *Pharmacol Res Perspect*. 2019 Dec;7(6):e00541.
14. Waxman DJ, Holloway MG. Sex differences in the expression of hepatic drug metabolizing enzymes. *Mol Pharmacol*. 2009 Aug;76(2):215–28.
15. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene

- expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther.* 2013 Apr;138(1):103–41.
16. Huang Y, Shan Y, Zhang W, Lee AM, Li F, Stranger BE, et al. Deciphering genetic causes for sex differences in human health through drug metabolism and transporter genes. *Nat Commun.* 2023 Jan 12;14(1):175.
 17. Oliva M, Muñoz-Aguirre M, Kim-Hellmuth S, Wucher V, Gewirtz ADH, Cotter DJ, et al. The impact of sex on gene expression across human tissues. *Science [Internet].* 2020 Sep 11;369(6509). Available from: <http://dx.doi.org/10.1126/science.aba3066>
 18. Padi M, Quackenbush J. Detecting phenotype-driven transitions in regulatory network structure. *NPJ Syst Biol Appl.* 2018 Apr 19;4:16.
 19. Lopes-Ramos CM, Chen CY, Kuijjer ML, Paulson JN, Sonawane AR, Fagny M, et al. Sex Differences in Gene Expression and Regulatory Networks across 29 Human Tissues. *Cell Rep.* 2020 Jun 23;31(12):107795.
 20. Lopes-Ramos CM, Kuijjer ML, Ogino S, Fuchs CS, DeMeo DL, Glass K, et al. Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. *Cancer Res.* 2018 Oct 1;78(19):5538–47.
 21. Paulson JN, Chen CY, Lopes-Ramos CM, Kuijjer ML, Platig J, Sonawane AR, et al. Tissue-aware RNA-Seq processing and normalization for heterogeneous and sparse data. *BMC Bioinformatics.* 2017 Oct 3;18(1):437.
 22. KimberlyGlass - Resources [Internet]. [cited 2023 Jan 4]. Available from: <https://sites.google.com/a/channing.harvard.edu/kimberlyglass/tools/resources?pli=1>
 23. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.* 2018 Jan 4;46(D1):D1074–82.
 24. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res.* 2021 Jan;49(D1):D605–12.
 25. Gene list functional enrichment analysis and namespace conversion with gprofiler2 [Internet]. 2021 [cited 2023 Mar 9]. Available from: <https://cran.r-project.org/web/packages/gprofiler2/vignettes/gprofiler2.html>
 26. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res.* 2016 Jan 4;44(D1):D457–62.
 27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A.* 2005 Oct 25;102(43):15545–50.
 28. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* 2015 Dec 23;1(6):417–25.
 29. Ben Guebila M, Wang T, Lopes-Ramos CM, Fanfani V, Weighill D, Burkholz R, et al. The

- Network Zoo: a multilingual package for the inference and analysis of gene regulatory networks. *Genome Biol.* 2023 Mar 9;24(1):1–23.
30. Wang JZ, Du Z, Payattakool R, Yu PS, Chen CF. A new method to measure the semantic similarity of GO terms. *Bioinformatics.* 2007 May;23(10):1274–81.
 31. Yu G, Li F, Qin Y, Bo X, Wu Y, Wang S. GOSemSim: an R package for measuring semantic similarity among GO terms and gene products. *Bioinformatics.* 2010 Apr;26(7):976–8.
 32. rrvgo [Internet]. Bioconductor. [cited 2022 Sep 12]. Available from: <https://bioconductor.org/packages/release/bioc/html/rrvgo.html>
 33. ComplexHeatmap [Internet]. Bioconductor. [cited 2022 Sep 12]. Available from: <https://bioconductor.org/packages/release/bioc/html/ComplexHeatmap.html>
 34. Abohelaika S, Wynne H, Avery P, Robinson B, Kesteven P, Kamali F. Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management. *Br J Clin Pharmacol.* 2016 Oct;82(4):1076–83.
 35. Burt LA, Billington EO, Rose MS, Kremer R, Hanley DA, Boyd SK. Adverse Effects of High-Dose Vitamin D Supplementation on Volumetric Bone Density Are Greater in Females than Males. *J Bone Miner Res.* 2020 Dec;35(12):2404–14.
 36. Lee I, Kaminski HJ, McPherson T, Feese M, Cutter G. Gender differences in prednisone adverse effects: Survey result from the MG registry. *Neurol Neuroimmunol Neuroinflamm.* 2018 Nov;5(6):e507.
 37. Kvien TK, Uhlig T, Ødegård S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. *Ann N Y Acad Sci.* 2006 Jun;1069:212–22.
 38. Diker-Cohen T, Amitai O, Shochat T, Shimon I, Tsvetov G. Denosumab-associated hypocalcemia: Does gender play a role? *Maturitas.* 2020 Dec;142:17–23.
 39. Tirona RG, Kim RB. Chapter 20 - Introduction to Clinical Pharmacology. In: Robertson D, Williams GH, editors. *Clinical and Translational Science (Second Edition)*. Academic Press; 2017. p. 365–88.
 40. Bangasser DA, Eck SR, Ordoñez Sanchez E. Sex differences in stress reactivity in arousal and attention systems. *Neuropsychopharmacology.* 2019 Jan;44(1):129–39.
 41. Glass K, Huttenhower C, Quackenbush J, Yuan GC. Passing messages between biological networks to refine predicted interactions. *PLoS One.* 2013 May 31;8(5):e64832.
 42. Li Y, Wang WJ, Cao H, Lu J, Wu C, Hu FY, et al. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. *Hum Mol Genet.* 2009 Dec 15;18(24):4897–904.
 43. Murtaza G, Khan AK, Rashid R, Muneer S, Hasan SMF, Chen J. FOXO Transcriptional Factors and Long-Term Living. *Oxid Med Cell Longev.* 2017 Aug 15;2017:3494289.
 44. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoeconomic and clinical aspects. *Pharmacol Ther.* 2007 Dec;116(3):496–526.

45. Sallinen J, Haapalinna A, Viitamaa T, Kobilka BK, Scheinin M. Adrenergic α 2C-Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice. *J Neurosci*. 1998 Apr 15;18(8):3035–42.
46. Smagin DA, Galyamina AG, Kovalenko IL, Kudryavtseva NN. Altered Expression of Genes Associated with Major Neurotransmitter Systems in the Reward-Related Brain Regions of Mice with Positive Fighting Experience. *Int J Mol Sci [Internet]*. 2022 Nov 7;23(21). Available from: <http://dx.doi.org/10.3390/ijms232113644>
47. Bhatia A, Lenchner JR, Saadabadi A. *Biochemistry, Dopamine Receptors*. StatPearls Publishing; 2022.
48. Golden SA, Jin M, Heins C, Venniro M, Michaelides M, Shaham Y. Nucleus Accumbens *Drd1*-Expressing Neurons Control Aggression Self-Administration and Aggression Seeking in Mice. *J Neurosci*. 2019 Mar 27;39(13):2482–96.
49. Park CI, Kim HW, Hwang SS, Kang JI, Kim SJ. Influence of dopamine-related genes on craving, impulsivity, and aggressiveness in Korean males with alcohol use disorder. *Eur Arch Psychiatry Clin Neurosci*. 2021 Aug;271(5):865–72.
50. Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. *Arch Neurol*. 1998 Oct;55(10):1335–40.
51. Oades RD, Lasky-Su J, Christiansen H, Faraone SV, Sonuga-Barke EJ, Banaschewski T, et al. The influence of serotonin- and other genes on impulsive behavioral aggression and cognitive impulsivity in children with attention-deficit/hyperactivity disorder (ADHD): Findings from a family-based association test (FBAT) analysis. *Behav Brain Funct*. 2008 Oct 20;4:48.
52. Aleyasin H, Flanigan ME, Golden SA, Takahashi A, Menard C, Pfau ML, et al. Cell-Type-Specific Role of Δ FosB in Nucleus Accumbens In Modulating Intermale Aggression. *J Neurosci*. 2018 Jun 27;38(26):5913–24.
53. Karlsson M, Zhang C, Méar L, Zhong W, Digre A, Katona B, et al. A single-cell type transcriptomics map of human tissues. *Sci Adv [Internet]*. 2021 Jul;7(31). Available from: <http://dx.doi.org/10.1126/sciadv.abh2169>
54. Gal-Oz ST, Maier B, Yoshida H, Seddu K, Elbaz N, Czysz C, et al. ImmGen report: sexual dimorphism in the immune system transcriptome. *Nat Commun*. 2019 Sep 20;10(1):4295.
55. Tsuchiya N, Honda ZI, Tokunaga K. Role of B cell inhibitory receptor polymorphisms in systemic lupus erythematosus: a negative times a negative makes a positive. *J Hum Genet*. 2006 Sep 1;51(9):741–50.
56. Koga M, Kawasaki A, Ito I, Furuya T, Ohashi J, Kyogoku C, et al. Cumulative association of eight susceptibility genes with systemic lupus erythematosus in a Japanese female population. *J Hum Genet*. 2011 Jul;56(7):503–7.
57. Morford J, Mauvais-Jarvis F. Sex differences in the effects of androgens acting in the central nervous system on metabolism. *Dialogues Clin Neurosci*. 2016 Dec;18(4):415–24.
58. Sever R, Glass CK. Signaling by nuclear receptors. *Cold Spring Harb Perspect Biol*. 2013 Mar

1;5(3):a016709.

59. Dotson AL, Wang J, Chen Y, Manning D, Nguyen H, Saugstad JA, et al. Sex differences and the role of PPAR alpha in experimental stroke. *Metab Brain Dis*. 2016 Jun;31(3):539–47.
60. Pierson-Marchandise M, Gras V, Moragny J, Micallef J, Gaboriau L, Picard S, et al. The drugs that mostly frequently induce acute kidney injury: a case - noncase study of a pharmacovigilance database. *Br J Clin Pharmacol*. 2017 Jun;83(6):1341–9.
61. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. *Nat Rev Dis Primers*. 2021 Jul 15;7(1):52.
62. Thong BYH, Tan TC. Epidemiology and risk factors for drug allergy. *Br J Clin Pharmacol*. 2011 May;71(5):684–700.
63. Eaddy Norton A, Broyles AD. Drug allergy in children and adults: Is it the double X chromosome? *Ann Allergy Asthma Immunol*. 2019 Feb;122(2):148–55.
64. Yoon S, Jeong S, Jung E, Kim KS, Jeon I, Lee Y, et al. Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem. *Sci Rep*. 2021 Sep 27;11(1):19150.
65. Davidson MD, Ballinger KR, Khetani SR. Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. *Sci Rep*. 2016 Jun 17;6:28178.
66. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. *J Clin Endocrinol Metab*. 2009 Mar;94(3):907–13.
67. Longo SK, Guo MG, Ji AL, Khavari PA. Integrating single-cell and spatial transcriptomics to elucidate intercellular tissue dynamics. *Nat Rev Genet*. 2021 Oct;22(10):627–44.
68. Williams CG, Lee HJ, Asatsuma T, Vento-Tormo R, Haque A. An introduction to spatial transcriptomics for biomedical research. *Genome Med*. 2022 Jun 27;14(1):68.
69. Eraslan G, Drokhlyansky E, Anand S, Fiskin E, Subramanian A, Slyper M, et al. Single-nucleus cross-tissue molecular reference maps toward understanding disease gene function. *Science*. 2022 May 13;376(6594):eabl4290.
70. Lu T, Mar JC. Investigating transcriptome-wide sex dimorphism by multi-level analysis of single-cell RNA sequencing data in ten mouse cell types. *Biol Sex Differ*. 2020 Nov 5;11(1):61.

Acknowledgements

We would like to thank all the members of the Lasseigne Lab for their feedback on this manuscript.

Funding

JLF and BNL were supported by R03OD030604; JLF, EFJ, and BNL were supported by R00HG009678; ADC and BNL are supported by U54OD030167; JLF, EJJ, and BNL are supported by UAB funds to the Lasseigne Lab.

Author information

Authors and Affiliations

Department of Cell, Developmental and Integrative Biology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA

Jennifer L. Fisher, Amanda D. Clark, Emma F. Jones, and Brittany N. Lasseigne

Contributions

Jennifer L. Fisher: Conceptualization, Methodology, Software, Formal Analysis, Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing, Visualization. Amanda D. Clark: Validation, Writing - Review & Editing. Emma F. Jones: Validation, Writing - Review & Editing. Brittany N. Lasseigne: Conceptualization, Resources, Writing - Review & Editing, Supervision, Project administration, Funding acquisition.

Corresponding author

Correspondence to Brittany N. Lasseigne.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Supplemental Information

Supplemental File 1: Computing system and package version information.

File name: FILE1_230512_computer_R_info.pdf

Detailed computer and package version information are included in **Supplemental File 1**.

Supplemental File 2: Number of samples for each GTEx tissue

File name: FILE2_gtex_tissue_counts.csv

The number of female and male RNA-Seq samples in Recount3 GTEx dataset **Supplemental File 2**. The gtex.sex column notes the sex. The gtex.smtsd column indicates the tissue. The Freq column indicates number of samples.

Supplemental File 3: Fisher's exact test results

File name: FILE3_drug_ae_res_info.csv

Supplemental File 3 contains all the the Fisher's exact test conducted with the MedDRA and DrugBank mappings.

- Drug - Drug Bank ID
- Adverse_event - MedDRA preferred term id
- a - the number of female patients with target drug-adverse event pairs
- b - the number of female patients with the drug but not the same adverse event,
- c - the number of male patients with target drug-adverse event pairs,
- d - the number of male patients with the drug but not the same adverse event.
- p-value - raw p-values from Fisher's exact test
- ROR- the reporting odds ratio
- conf_1 - lower boundary of the confidence interval 95%
- conf_2- upper boundary of the confidence interval 95%
- BH - BH adjusted p-value from the raw p-values from Fisher's exact test
- comb- Drug Bank ID and MedDRA id
- neg_log_p - negative log BH adjusted p-value
- logROR - log reporting odds ratio
- color - color for plotting
- pt_id - MedDRA preferred term id
- pt_term - MedDRA preferred term
- soc_id - MedDRA system organ class term id
- soc_term - MedDRA system organ class term
- soc_short - MedDRA system organ class short term
- drug_name - drug name
- drug_id - Drug Bank ID

Supplemental File 4: ALPACA pathway results for the core genes of the sex-specific communities across tissues.

File name: FILE4_all_pathways.csv

Supplemental File 4 contains gprofiler2 functional enrichment of the ALPACA sex-specific network communities. The set column was added to the gprofiler2 output to note if enriched gene sets were from which core gene lists: set - the tissue sex-specific community, tissue- tissue, sex- sex, and comm_num- community number for the tissue sex-specific community gene list. The columns query, significant, p_value, term_size, query_size, intersection_size, precision, recall, term_id, source, term_name, effective_domain_size, and source_order are from the gprofiler2 output. Below is the column information from the gprofiler vignette:[25]

- query - the name of the input query which by default is the order of the query with the prefix "query_." This can be changed by using a named list input.
- significant - indicator for statistically significant results
- p_value - hypergeometric p-value after correction for multiple testing
- term_size - number of genes that are annotated to the term
- query_size - number of genes that were included in the query. This might be different from the size of the original list if:
 - any genes were mapped to multiple Ensembl gene IDs
 - any genes failed to be mapped to Ensembl gene IDs
- the parameter ordered_query = TRUE and the optimal cutoff for the term was found before the end of the query
- the domain_scope was set to "annotated" or "custom"
- intersection_size - the number of genes in the input query that are annotated to the corresponding term

- precision - the proportion of genes in the input list that are annotated to the function (defined as $\text{intersection_size}/\text{query_size}$)
- recall - the proportion of functionally annotated genes that the query recovers (defined as $\text{intersection_size}/\text{term_size}$)
- term_id - unique term identifier (e.g GO:0005005)
- source - the abbreviation of the data source for the term (e.g. GO:BP)
- term_name - the short name of the function
- effective_domain_size - the total number of genes “in the universe” used for the hypergeometric test
- source_order - numeric order for the term within its data source (this is important for drawing the results)

Supplemental File 5:

File name: FILE5_liver_edge_differences_pathways.csv

Supplemental File 5 contains the GO semantic similarity analysis results from gprofiler2 functional enrichment of the unique sex-specific activator and repressor edges.

- go - GO Biological Process ID
- cluster - cluster number
- parent - the common parent GO term ID
- parentSimScore - the fraction of genes of the GO term shared with the common parent GO term
- score - The number genes in the GO term (same as size)
- size - The number genes in the GO term (same as score)
- term - the Biological Process GO term
- parentTerm - the common parent GO term group
- female_act_list - TRUE or FALSE if the listed GO term is enriched in the female activator targeted edges
- female_repress_list - TRUE or FALSE if the listed GO term is enriched in the female repressor targeted edges
- male_act_list - TRUE or FALSE if the listed GO term is enriched in the male activator targeted edges
- male_repress_list - TRUE or FALSE if the listed GO term is enriched in the male repressor targeted edges

Supplemental File 6:

File name: FILE6_drug_info_sbae_drugs.xls

Supplemental File 6 contains SBAE-associated drugs' DrugBank ID (drug_id), known drug targets (targets), drug metabolism enzymes (enzyme), transporters (transporter), and carrier (carrier). This file also contains the list of SBAE-associated drug targets (SBAE_Drug_Targets) and drug metabolism enzymes (SBAE_Drug_ENZ).